Kidney Transplantation
Conditions
Keywords
Arteriovenous Fistula
Brief summary
The aim of the project is to assess the effect of functioning AVF in renal transplant patients on fibrosis, inflammation and LVH indicators. Clinical and laboratory parameters will be compared in a group of 150 patients, 75 patients with a functioning fistula and 75 patients with inactive vascular access. We will assess the impact of functional AVF and the levels of biomarkers on the survival of patients and transplanted kidneys.
Detailed description
Patients after kidney transplantation during a routine visit will be asked to participate to the study. In eligible a number of studies will be conducted: * detailed clinical examination * routine laboratory tests * lung ultrasound * muscle strength with a dynamometer * ultrasound assessment of upper limb vessels with assessment of fistula function (in the case of active fistula) and for the possibility of future vascular access * blood collection and protection (10-15 ml) for biomarkers * survey EQ-5D-5L and LVD-36 * functional strength test. The obtained clinical data and test results will be subject to statistical analysis after anonymization. The impact of individual parameters on long-term prognosis will be assessed.
Interventions
OTHERpresence of AVF
Functioning AVF may have cardiotoxic potential
Sponsors
Wroclaw Medical University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age\> 18 years old * kidney transplant * \>12 months after transplantation * stable transplanted kidney function * signed informed consent
Exclusion criteria
* GFR \<15 ml / min * severe infection within 3 months of testing * increase in creatinine concentration\> 0.5 mg / dl within 3 months before the test * active cancer * signs of severe heart failure (NYHA IV)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life with EQ-5D-5L | Baseline visit up to 12 months | The survey results will be compared between the study and control groups to see if the presence of the arteriovenous fistula affects quality of life. |
| Prognostic value of biomarkers (NT-proBNP, Il-6, sST2, galectin-3, GDF-15, MMP7, TIMP1) | Baseline visit and up to 12 months | The levels of biomarkers will be measured and the results will be compared between the study and control groups. A prognostic value of the biomarkers will be estimated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalization-free survival | Up to 12 months from baseline visit | Hospital-free survival will be reported as the number of patients living 12 months after the initial visit without the need for hospitalization. |
Countries
Poland
Contacts
Primary ContactKrzysztof Letachowicz, MD, PhD
Outcome results
None listed